Clinical effects of 0.1% hydrocortisone-17-butyrate ointment (vehicle: plastibase, hereinafter H·17 B·O in short) and 0.1% hydrocortisone-17-butyrate cream (vehicle: hydrophilic ointment, hereinafter H·17 B·C in short) were examined by SA (simple administration) or ODT (occlusive dressing technique) methods in cooperation with the 11 institutes on inflamatory dermatological diseases; acute eczematoid dermatitis, seborrheic eczema, chronic eczema, atopic dermatitis psoriasis vulgaris, hand dermatitis (especially keratodermia tyloydes palmaris progressiva), prurigo and palmoplanter pustlosis and the following results were obtained. 1) H·17 B·O and H·17 B·C were administered to 378 cases (171 cases for H·17 B·O and 207 cases for H·17 B·C). The cases treated with H·17 B·O indicated the effective ratio of 152/171=88.9% while those with H·17 B·C 195/207=94.2%, making the efficacy of H·17 B 91.8% (347/378). 2) When compared with betamethasone valerate, fluocinolone acetonide and triamcinolone acetonide, H·17 B seemed to be equal in effect to betamethasone valerate and superior to the other two drugs. 3) Side effects were observed in one case treated with H·17 B O and six cases with H·17 B·C without any serious ones. One case treated with H·17 B·O produced slight burning. Out of the cases treated with H·17 B·C, follicultis in four cases, slight dermatitis in one case and xerodermous skin in one case were observed.